Soon after the identification of the breast cancer predisposition genes BRCA1 and BRCA2, mutation screening of families burdened with a substantial history of breast and ovarian cancer, became a routine demand, since it aids the identification of individuals at high risk. This evidence concerns the gene BRCA2 and breast cancer.